ES2400107T3 - IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado - Google Patents

IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado Download PDF

Info

Publication number
ES2400107T3
ES2400107T3 ES08840928T ES08840928T ES2400107T3 ES 2400107 T3 ES2400107 T3 ES 2400107T3 ES 08840928 T ES08840928 T ES 08840928T ES 08840928 T ES08840928 T ES 08840928T ES 2400107 T3 ES2400107 T3 ES 2400107T3
Authority
ES
Spain
Prior art keywords
ifn
compound
beta
arm
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08840928T
Other languages
English (en)
Spanish (es)
Inventor
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Philippe Dupraz
Christine Power
Laurent Magnenat
Philippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Gian Battista Bozzato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of ES2400107T3 publication Critical patent/ES2400107T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08840928T 2007-10-22 2008-10-21 IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado Active ES2400107T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07118980 2007-10-22
EP07118980 2007-10-22
US714207P 2007-12-11 2007-12-11
US7142P 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (1)

Publication Number Publication Date
ES2400107T3 true ES2400107T3 (es) 2013-04-05

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08840928T Active ES2400107T3 (es) 2007-10-22 2008-10-21 IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado

Country Status (6)

Country Link
EP (1) EP2203180B1 (enExample)
JP (1) JP5314033B2 (enExample)
AU (1) AU2008314697B2 (enExample)
ES (1) ES2400107T3 (enExample)
IL (1) IL204948A (enExample)
WO (1) WO2009053368A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534399A (en) 2002-01-25 2008-08-29 G2 Therapies Ltd Monoclonal antibodies against extracellular loops of C5aR
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN104193824A (zh) 2008-02-20 2014-12-10 G2炎症私人有限公司 人源化抗-C5aR抗体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
TWI638833B (zh) * 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
PL2718322T3 (pl) * 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
KR102568808B1 (ko) 2014-04-07 2023-08-18 추가이 세이야쿠 가부시키가이샤 면역활성화 항원 결합 분자
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR20210013299A (ko) * 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA49339A (fr) * 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
CA3121699A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
PH12021552960A1 (en) 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20230159831A (ko) * 2021-02-22 2023-11-22 압데라 테라퓨틱스 인크. 표적화된 방사성 동위원소 요법을 위한 면역접합체
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
US12600794B2 (en) 2024-07-23 2026-04-14 Abdera Therapeutics Inc. 5T4 binding polypeptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100480266C (zh) * 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
JP2006513139A (ja) * 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2006207471A1 (en) * 2005-01-24 2006-07-27 Laboratoires Serona S.A. Use of soluble CD164 variants in inflammatory and/or autoimmune disorders
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.

Also Published As

Publication number Publication date
WO2009053368A1 (en) 2009-04-30
IL204948A (en) 2015-11-30
EP2203180A1 (en) 2010-07-07
EP2203180B1 (en) 2012-11-21
JP2011500073A (ja) 2011-01-06
AU2008314697A1 (en) 2009-04-30
AU2008314697B2 (en) 2013-08-29
JP5314033B2 (ja) 2013-10-16
IL204948A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
AU2008314697B2 (en) Single IFN-beta fused to a mutated lgG Fc fragment
JP6329585B2 (ja) 単量体抗体Ｆｃ
TWI667255B (zh) 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP5781501B2 (ja) 改変されたＦｃＲｎ結合部位を有する抗体融合タンパク質
TWI667258B (zh) 因子ｖｉｉｉ與ｘｔｅｎ及范威爾邦德（ｖｏｎ ｗｉｌｌｅｂｒａｎｄ）因子蛋白質之複合物及其用途
KR102276157B1 (ko) 고글리코실화 인간 혈액응고인자 viii 융합 단백질 및 그 제조방법과 용도
ES2428894T3 (es) Inmunoglobulina glicosilada e inmunoadhesina que la comprende
CZ25697A3 (en) Novel compounds
CN105073781A (zh) 牛融合抗体
JP2015503349A5 (enExample)
JP2012532608A (ja) ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
KR102722304B1 (ko) Uti 융합 단백질
ES3014555T3 (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity
AU2020336980B2 (en) Antibody compositions and methods for treating hepatitis B virus infection
JP2021509590A (ja) ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法
JP2023551667A (ja) 抗－インフルエンザ抗体及びその組合せ
CN117412989A (zh) 具有改进的特性的双功能分子的新支架
JP2023551666A (ja) Ａ型インフルエンザウイルスに対する抗体
HK1168607A (en) Antibody fusion proteins with modified fcrn binding sites
AU2015201449A1 (en) Carrier Immunoglobulins And Uses Thereof